Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients.

Baird RD, van Rossum AGJ, Oliveira M, Beelen K, Gao M, Schrier M, Mandjes IAM, Garcia-Corbacho J, Vallier AL, Dougall G, van Werkhoven E, Linossi C, Kumar S, van Tinteren H, Callari M, Beddowes E, Perez-Garcia JM, Rosing H, Platte E, Nederlof P, Schot M, de Vries Schultink A, Bernards R, Saura C, Gallagher W, Cortès J, Caldas C, Linn SC.

Clin Cancer Res. 2019 Nov 15;25(22):6598-6605. doi: 10.1158/1078-0432.CCR-19-0508. Epub 2019 Aug 22.

PMID:
31439579
2.

Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort.

de Vries Schultink AHM, Crombag MBS, van Werkhoven E, Otten HM, Bergman AM, Schellens JHM, Huitema ADR, Beijnen JH.

Cancer Med. 2019 Apr;8(4):1406-1415. doi: 10.1002/cam4.2003. Epub 2019 Feb 22.

3.

Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice.

Crombag MBS, de Vries Schultink AHM, van Doremalen JGC, Otten HM, Bergman AM, Schellens JHM, Beijnen JH, Huitema ADR.

Drugs Aging. 2019 Apr;36(4):379-385. doi: 10.1007/s40266-019-00643-2.

PMID:
30734241
4.

Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study.

Crombag MBS, de Vries Schultink AHM, Koolen SLW, Wijngaard S, Joerger M, Schellens JHM, Dorlo TPC, van Erp NP, Mathijssen RHJ, Beijnen JH, Huitema ADR.

Pharm Res. 2019 Jan 7;36(2):33. doi: 10.1007/s11095-018-2563-6.

PMID:
30617624
5.

Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy.

de Vries Schultink AHM, Huitema ADR, Beijnen JH.

Breast. 2018 Dec;42:38-40. doi: 10.1016/j.breast.2018.08.100. Epub 2018 Aug 22.

PMID:
30153552
6.

Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen.

van Nuland M, Vreman RA, Ten Ham RMT, de Vries Schultink AHM, Rosing H, Schellens JHM, Beijnen JH, Hövels AM.

Breast Cancer Res Treat. 2018 Nov;172(1):143-150. doi: 10.1007/s10549-018-4886-8. Epub 2018 Jul 13.

7.

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.

de Vries Schultink AHM, Doornbos RP, Bakker ABH, Bol K, Throsby M, Geuijen C, Maussang D, Schellens JHM, Beijnen JH, Huitema ADR.

Invest New Drugs. 2018 Dec;36(6):1006-1015. doi: 10.1007/s10637-018-0593-x. Epub 2018 May 5.

8.

Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.

de Vries Schultink AHM, Boekhout AH, Gietema JA, Burylo AM, Dorlo TPC, van Hasselt JGC, Schellens JHM, Huitema ADR.

J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):431-442. doi: 10.1007/s10928-018-9579-8. Epub 2018 Feb 10.

9.

Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis.

Bastida C, Ruiz-Esquide V, Pascal M, de Vries Schultink AHM, Yagüe J, Sanmartí R, Huitema ADR, Soy D.

Br J Clin Pharmacol. 2018 Apr;84(4):716-725. doi: 10.1111/bcp.13500. Epub 2018 Feb 7.

10.

Pharmacokinetics and excretion of 14C-Plitidepsin in patients with advanced cancer.

van Andel L, Fudio S, Rosing H, Munt S, Miguel-Lillo B, González I, Tibben MM, de Vries N, de Vries Schultink AHM, Schellens JHM, Beijnen JH.

Invest New Drugs. 2017 Oct;35(5):589-598. doi: 10.1007/s10637-017-0432-5. Epub 2017 Jan 23.

PMID:
28111728
11.

An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome.

de Vries Schultink AH, Alexi X, van Werkhoven E, Madlensky L, Natarajan L, Flatt SW, Zwart W, Linn SC, Parker BA, Wu AH, Pierce JP, Huitema AD, Beijnen JH.

Breast Cancer Res Treat. 2017 Feb;161(3):567-574. doi: 10.1007/s10549-016-4083-6. Epub 2016 Dec 22.

12.

Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment.

de Vries Schultink AH, Suleiman AA, Schellens JH, Beijnen JH, Huitema AD.

Eur J Clin Pharmacol. 2016 Jun;72(6):645-53. doi: 10.1007/s00228-016-2030-4. Epub 2016 Feb 26. Review.

13.

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.

de Vries Schultink AH, Zwart W, Linn SC, Beijnen JH, Huitema AD.

Clin Pharmacokinet. 2015 Aug;54(8):797-810. doi: 10.1007/s40262-015-0273-3. Review.

14.

Stability of colistimethate sodium in a disposable elastomeric infusion device.

Abdulla A, van Leeuwen RW, de Vries Schultink AH, Koch BC.

Int J Pharm. 2015;486(1-2):367-9. doi: 10.1016/j.ijpharm.2015.04.008. Epub 2015 Apr 8.

PMID:
25863116
15.

Incidence of hematologic toxicity in older adults treated with gemcitabine or a gemcitabine-containing regimen in routine clinical practice: a multicenter retrospective cohort study.

Crombag MR, de Vries Schultink AH, Schellens JH, Beijnen JH, Huitema AD.

Drugs Aging. 2014 Oct;31(10):737-47. doi: 10.1007/s40266-014-0207-z.

PMID:
25216600

Supplemental Content

Loading ...
Support Center